AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech AMIX Autonomix Secures U.S. Patent For Overactive Bladder Diagnosis, Treatment Platform July 16, 2026 — 03:29 am EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Autonomix Medical, Inc. (AMIX), a medical device company, announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,611,134 covering its platform for the diagnosis and treatment of overactive bladder. The patent, titled "Devices, Systems, and Methods for Diagnosis and Treatment of Overactive Bladder," expands the company's proprietary neural sensing and therapeutic technology into the urology market. The overactive bladder according to the company affects an estimated 37 million Americans and is associated with significant healthcare costs and reduced quality of life. The patented platform supports a catheter-based, minimally invasive "Sense. Treat. Verify." approach that detects abnormal bladder nerve activity and delivers targeted therapy, including radiofrequency ablation or localised drug delivery. The platform also verifies treatment effectiveness through real-time electrophysiological feedback. In addition, the patent covers an implantable bladder device designed for long-term monitoring of bladder pressure and electrophysical signals, as well as localised therapy. Brad Hauser, Chief Executive Officer, said the patent extends the company's neural sensing technology into a large new clinical indication and strengthens its intellectual property portfolio in nerve-targeted therapies. Company Profile Autonomix Medical is a medical device company developing a catheter-based neural sensing and ablation platform designed to diagnose and treat diseases involving the peripheral nervous system through minimally invasive, precision nerve-targeted therapies. AMIX closed Wednesday's trade down 1.16% at $5.13. In the overnight market, AMIX is trading up 1.36% at $5.20. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags BioTech RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source -> Stocks mentioned AMIX More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.